Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration. “I think there is definitely ideologic support from the Trump administration, or allies of the incoming Trump administration, for getting rid of the negotiation program,” she added. Eliminating Medicare negotiations would be politically risky for Trump, Mulcahy said. “Supporting negotiations for a lower price for Ozempic would be a win-win for Trump,” Gostin said. “There are compelling political reasons to support drug price negotiations,” Gostin said.

---

Persons: Joe Biden —, Trump, Ibrance, Donald Trump’s, bode, Juliette Cubanski, ” Cubanski, we’ve, Biden, Johnson, Robert F, Kennedy Jr, Andrew Mulcahy, Barack, Mulcahy, KFF, haven’t, we’re, ” Mulcahy, Ozempic, Cubanski, Lawrence Gostin, ” Gostin, ” Organizations: drugmakers, Medicare, Bristol Myers Squibb, Imbruvica, Novo Nordisk, Trump, Department of Health, Human Services, Rand Corporation, Democratic, O’Neill Institute for National, Global Health Law, Georgetown University, “ Locations: United States, AbbVie, Novo